About Qurin Diagnostics
Qurin Diagnostics is a company based in Amsterdam (Netherlands) founded in 2017. It operates as a B2B and Partnership-based. Qurin Diagnostics offers products and services including Biomarker Extraction Technology and Urine-based Sample Collection System.
- Headquarter Amsterdam, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Qurin Diagnostics
Qurin Diagnostics offers a comprehensive portfolio of products and services, including Biomarker Extraction Technology and Urine-based Sample Collection System.
Amplifies cancer signals from urine for accurate early detection
Enables non-invasive collection and pre-concentration for cancer testing
Funding Insights of Qurin Diagnostics
Detailed funding history for Qurin Diagnostics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qurin Diagnostics
Investment portfolio details for Qurin Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Qurin Diagnostics
Detailed financials for Qurin Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qurin Diagnostics Comparisons
Peer comparison for Qurin Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Qurin Diagnostics
Detailed competitors of Qurin Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qurin Diagnostics
Complete news archive for Qurin Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qurin Diagnostics
Qurin Diagnostics was founded in 2017.
Qurin Diagnostics is headquartered in Amsterdam, Netherlands.
Qurin is a diagnostic biotech company that creates patented technology for early cancer detection, focusing on non-invasive sample collection and biomarker extraction from urine. It improves test accuracy for cancers like bladder cancer by amplifying signals and integrating with existing workflows. The company partners with researchers and is based in Leiden, Netherlands, aiming to reduce healthcare burdens through innovative diagnostics.
Qurin Diagnostics offers Biomarker Extraction Technology and Urine-based Sample Collection System.